Provided is a human monoclonal antibody specific for LPS of the P. aeruginosa serotype IATS 01. The binding of 216-01 to LPS isolated from P. aeruginosa strains was determined by ELISA.
Figure 1 relates to the recognition pattern of LPS isolated from P. aeruginosa strains by the monoclonal antibody 216-01. The binding of 216-01 was determined by ELISA.
Figure 2 relates to the opsonophagocytotic activity of the monoclonal antibody 216-01 and two other known antibodies (MAb C1 and MAb C2) directed against P. aeruginosa serotype IATS 01.
Figure 3 relates to the pharmocodynamics of the monoclonal antibody 216-01 in mice.
The in vivo protective capacity of 216O1 was assessed in a murine burn wound sepsis model. Different doses of 21601 were administered i.v. to NMRI mice. Survival rates are shown up to 96 h after challenge.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
NABL-060 | Recombinant Anti-V. cholerae O1 LPS VHH Single Domain Antibody | WB, ELISA, IP, FuncS | Llama VHH |
There are currently no Customer reviews or questions for HPAB-J0169-YC. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.